SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Evofem
Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference
call to discuss the Company's financial results and business
highlights for the fourth quarter and year ended December 31, 2020 as follows:
Date
|
Thursday, March 4,
2021
|
Time
|
4:30 p.m. ET (1:30
p.m. PT)
|
Webcast (live and
archived)
|
www.evofem.com
under "Investors"
|
Dial-in
numbers
|
(866) 503-5561 (U.S.
toll-free) or (253) 336-2965
|
Conference
ID
|
9928997
|
The live webcast and related slide presentation can be accessed
through the Investors section of its website or directly at
https://evofem.investorroom.com/Q4YE2020Results. Please
connect to the Company's website at least 15 minutes prior to the
start of the call to download any software that may be
required.
If participating by phone, please dial in approximately 15
minutes prior to the start of the call.
The webcast will be archived at
https://evofem.investorroom.com/Q4YE2020Results. A telephone replay
will be available for 24 hours after the call at (855)
859-2056 (U.S.) or (404) 537-3406 (International), conference
ID 9928997.
About Evofem Biosciences, Inc.
Evofem Biosciences,
Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical
company committed to developing and commercializing innovative
products to address unmet needs in women's sexual and reproductive
health, including hormone-free, woman-controlled contraception and
protection from certain sexually transmitted infections (STIs). The
Company's first commercial product, Phexxi® (lactic
acid, citric acid and potassium bitartrate), is the first and
only hormone-free, prescription vaginal gel approved in the
United States for the prevention of pregnancy. The Company's
lead product candidate, EVO100, is being evaluated for the
prevention of urogenital Chlamydia
trachomatis and Neisseria
gonorrhoeae infection in women in
the ongoing Phase 3 clinical
trial, 'EVOGUARD.' For more information, please
visit www.evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact
Ellen
Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-fourth-quarter-and-year-end-2020-results-and-provide-corporate-update-on-thursday-march-4-2021-301230571.html
SOURCE Evofem Biosciences, Inc.